ChAdOx2 RabG

BIOLOGICAL2 trials

Sponsors

University of Oxford

Conditions

Rabies

Phase 1

Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG

TerminatedNCT04162600

University of OxfordRabies

Start: 2020-01-02End: 2024-07-10Updated: 2024-11-08

A Phase Ib/II Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG

Active, not recruitingNCT04270838

University of OxfordRabies

Start: 2022-02-17End: 2028-09-30Updated: 2025-11-18

Related Papers

Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial.

2022-07-2720 citations